Travere Therapeutics (TVTX) Enterprise Value (2013 - 2026)
Travere Therapeutics (TVTX) posted Enterprise Value of -$78.4 million for Q1 2026, up 15.77% on a QoQ basis from -$93.0 million in Q4 2025, and down 26.6% year-over-year from -$106.8 million in Q1 2025.
Travere Therapeutics (TVTX) Enterprise Value (2013 - 2026) Analysis & Trends
Travere Therapeutics' Enterprise Value history runs 14 years deep, the most recent figure standing at -$78.4 million for Q1 2026.
- Quarterly Enterprise Value fell 26.6% year-over-year to -$78.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$78.4 million (down 26.6% YoY) and the FY2025 annual result came in at -$93.0 million, down 58.94% from the prior year.
- Enterprise Value was -$78.4 million for Q1 2026 at Travere Therapeutics, up from -$93.0 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$32.3 million in Q2 2024 and bottomed at -$256.6 million in Q1 2022.
- A 5-year average of -$98.5 million and a median of -$75.2 million in 2025 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2024 — Enterprise Value soared 74.76% — and 2025, when it slumped 204.68%.
- Travere Therapeutics' Enterprise Value stood at -$61.7 million in 2022, then rose by 5.69% to -$58.2 million in 2023, then fell by 0.62% to -$58.5 million in 2024, then plunged by 58.94% to -$93.0 million in 2025, then gained by 15.77% to -$78.4 million in 2026.
- Business Quant data shows TVTX's Enterprise Value at -$78.4 million in Q1 2026, -$93.0 million in Q4 2025, and -$110.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -1.91 Bn |
| 10 | Travere Therapeutics | 5.21 Bn | 5.21 Bn | 125.25 Mn | -78.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -78.36 Mn |
| Dec 31, 2025 | -93.04 Mn |
| Sep 30, 2025 | -110.93 Mn |
| Jun 30, 2025 | -75.15 Mn |
| Mar 31, 2025 | -61.90 Mn |
| Dec 31, 2024 | -58.54 Mn |
| Sep 30, 2024 | -36.41 Mn |
| Jun 30, 2024 | -32.29 Mn |
| Mar 31, 2024 | -43.25 Mn |
| Dec 31, 2023 | -58.18 Mn |
| Sep 30, 2023 | -144.24 Mn |
| Jun 30, 2023 | -70.87 Mn |
| Mar 31, 2023 | -161.38 Mn |
| Dec 31, 2022 | -61.69 Mn |
| Sep 30, 2022 | -151.34 Mn |
| Jun 30, 2022 | -179.76 Mn |
| Mar 31, 2022 | -256.57 Mn |
| Dec 31, 2021 | -165.75 Mn |
| Sep 30, 2021 | -150.33 Mn |
| Jun 30, 2021 | -83.29 Mn |